improvement within 1 week. By 3 months, he returned to his neuropsychological baseline in majority of cognitive domains from moderate-severe dysfunction, with concurrent MRI demonstrating resolving white matter lesions and FFA showing less evident vasculitis. The treatment response was maintained with tapering of steroids (25mg at 12 months). He was able to return to his previous occupation as a paramedic by 1 year.

Conclusion SuS is a rare, immune-mediated microangiopathy in which early recognition with aggressive immunosuppression is required to achieve optimal outcome. No randomized controlled trial (RCT) exists for the management of this condition. In this report, early recognition through multidisciplinary input and aggressive immunotherapy with rituximab resulted in a favourable outcome. However, RCT evidence is needed to guide management.

113 CLINICAL AND NEUROPHYSIOLOGICAL IMPROVEMENT IN HEREDITARY SENSORY AND AUTONOMIC NEUROPATHY TYPE I (HSAN-1) FOLLOWING HIGH DOSE SERINE THERAPY

¹James D Triplett, ^{1,2,3}Garth Nicholson, ^{1,2,4}Con Yiannikas. ¹Department of Neurology and Neurophysiology, Concord Repatriation General Hospital, Sydney, Australia, Concord, NSW, Australia; ²Sydney Medical School, University of Sydney, Sydney, NSW, Australia; ³Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, NSW, Australia; ⁴Department of Neurology, Royal North Shore Hospital, Sydney, NSW, Australia

10.1136/bmjno-2021-ANZAN.113

Objective To report clinical stabilisation and improved summated compound motor action potentials (CMAP) in a patient with Hereditary sensory and autonomic neuropathy type I (HSAN-1) following high dose serine therapy.

Case A 52-year-old male presented in 2006 with a typical HSAN-1c phenotype and over the ensuing years had progressive distal to proximal sensory disturbance, associated lancinating pains, and mild progressive distal predominant limb weakness. A Ser384Phe mutation in the SPTLC2 gene located on chromosome 14q24 was identified in this patient in 2017. In late 2018 high dose serine therapy (11 grams TDS) was commenced, resulting in stabilisation of clinical weakness.

Lower limb motor and sensory responses were absent at presentation in 2006 with initial summated bilateral upper-limb median and ulnar nerve CMAP being 31.2mV and steadily declining to 4.2mV in March 2019. Following Serine therapy, the summated CMAP increased to 5.4mV in August 2020 and 9.5mV in February 2021, furthermore previously absent upper-limb sensory nerve responses are now recordable.

Conclusions High dose Serine replacement therapy may lead to clinical stabilisation and improved neurophysiological parameters in HSAN-1. HSAN-1, an autosomal dominant sensory neuropathy occurs secondary to mutations in the enzyme Serine-Palmitoyltransferase (SPT), an essential enzyme in the de-novo synthesis of sphingolipids. The administration of high dose Serine may overcome altered SPT substrate specificity in HSAN-1, which preferentially uses L-alanine and L-glycine instead of L-serine and allow the formation of typical 1-deoxysphingolipids as opposed to atypical 1-deoxysphingolipids generally seen in this condition, with early treatment possibly preventing clinical progression.

114 MAN-IN-THE-BARREL SYNDROME AS A COMPLICATION OF CERVICAL DECOMPRESSIVE SURGERY

Rajiv Wijesinghe, Con Yiannikas. Department of Neurology, Concord Repatriation General Hospital, Concord, NSW, Australia

10.1136/bmjno-2021-ANZAN.114

Objective To present a case of painful brachial diplegia following cervical decompressive surgery.

Case A 73 year-old male presented with a 6 month history tripping over his left leg, resulting in near falls. An MRI demonstrated severe spondylotic cervical canal stenosis at C4/5 with myelomalacia and he subsequently underwent a cervical decompression and fusion at this level. On post-operative day five he developed severe pain in his neck and shoulders and mild weakness of his left arm. One week later he underwent a second operation with decompression and rhizolysis at C5 to C8. On post-operative day 3 he awoke with severe pain similar to previously, followed a day later by profound weakness of all movements around the shoulders bilaterally, but movements around the elbows, wrists and fingers were normal. While walking his arms hung limply beside him, giving him the appearance of a man in a barrel. Routine nerve conduction studies and median somatosensory evoked potentials were normal. Electromyography confirmed denervation within the C5 myotome bilaterally, however with selective sparing of the rhomboids bilaterally. This suggested a lesion distal to the branch to rhomboids, and a diagnosis of bilateral post-operative brachial neuritis was made.

Conclusion Acute proximal arm weakness is an uncommon complication of cervical surgeries, referred to commonly as a post-operative C5 palsy. Investigations performed in this case however suggest that a brachial plexus lesion may be the cause of this peculiar syndrome. This syndrome may lie on the spectrum of post-surgical inflammatory neuropathies.

115 ERRONEOUSLY NORMAL ACTIVE B12 LEVEL IN A CASE OF SUBACUTE COMBINED DEGENERATION OF THE CORD

¹Nicholas Halliwell, ²Cecily Forsyth, ³Nicholas Taylor, ²Sarah Mangalasseril, ¹Jonathan Sturm. ¹Neurology, Gosford Hospital, Gosford, NSW, Australia; ²Haematology, Gosford Hospital, Gosford, NSW, Australia; ³Clinical Biochemistry, Douglass Hanly Moir Pathology, Wentworth, NSW, Australia

10.1136/bmjno-2021-ANZAN.115

Objectives Vitamin B12 is crucial for neurologic function, red blood cell production, and DNA synthesis. Deficiency can lead to a wide spectrum of haematologic and neuropsychiatric disorders including subacute combined degeneration of the cord. This report presents a case of a 47 y.o female who presented with subacute combined degeneration of the spinal cord with a normal active B12 level.

Results MRI demonstrated high T2 signal throughout the dorsal columns of the cervical and upper thoracic cord without enhancement consistent with subacute combined degeneration of the cord. Her blood count revealed a mild macrocytic anaemia. Total vitamin B12 was <80 pmol/L and active B12 was >128 pmol/L, confirmed on repeat testing. Functional vitamin B12 deficiency was confirmed by an elevated homocysteine level of 38.6 umol/L (reference range 4.4 to 13.6 umol/L) and elevated serum methylmalonic acid of 20.75

umol/L (reference range <0.32 umol/L). Intrinsic factor and gastric parietal cell antibodies were detected.

Conclusion Our patient had a clinical presentation consistent with B12 deficiency with an erroneously high active B12 level. Functional assays confirmed B12 deficiency, and a serological diagnosis of pernicious anaemia was made. This case illustrates the importance of not relying on any single test to exclude B12 deficiency.

116

PARANEOPLASTIC PROGRESSIVE-SUPRANUCLEAR PALSY LIKE BRAINSTEM SYNDROME ASSOCIATED WITH LUNG ADENOCARCINOMA

¹Natasha Gerbis, ²Ariadna Fontes-Villalba, ^{3,4}Patrick Aouad, ^{2,3}Suran Fernando, ^{2,3}John DE Parratt. ¹Northern Beaches Hospital, Frenchs Forest, NSW, Australia; ²Royal North Shore Hospital, St Leonards, NSW, Australia; ³University of Sydney, Sydney, NSW, Australia; ⁴Liverpool Hospital, Sydney, NSW, Australia

10.1136/bmjno-2021-ANZAN.116

Objectives Progressive supranuclear palsy (PSP) is a neurodegenerative condition characterised by Parkinsonian features, cervical dystonia and ophthalmoparesis. Paraneoplastic PSP has previously been reported in the literature in association with several different cancer types but is very rare.^{1–3}

Methods Case review.

Results A 74 year old Chinese man was diagnosed with Stage 1b EGFR positive lung adenocarcinoma and underwent a left upper lobectomy. Twelve months later he presented with rapidly progressive neck stiffness, reduction in motor function and gait (over 8 weeks) and recalcitrant disequilibrium.

He had hypomimia, frontalis over-activation, blepharospasm, blepharotremor and a supranuclear gaze palsy. There was marked axial rigidity, bradykinesia and cervical dystonia. An MRI brain and spine were unremarkable. Vestibular function tests were normal. Serum antineuronal antibodies were negative. The CSF analysis was unremarkable.

The patient responded to plasma exchange on a two to three-weekly basis with significant improvement in saccadic eye movements and Parkinsonism. However, disequilibrium remained a persistent problem despite the discovery and excision of a second EGFR wild type non-small cell lung cancer, and Rituximab was recently started. Cervical dystonia was treated partially with Botulinum toxin injections, but the patient responded poorly to L-dopa.

Conclusions This suspected paraneoplastic disease exhibits several features of PSP. In particular, the supranuclear palsy, Parkinsonism and dystonia are similar to the typical syndrome. However, the rapidly progressive presentation and disequilibrium are unusual and a response to plasma exchange, suggests humorally mediated neuronal pathology. In rapidly evolving PSP-like cases with cancer, investigation for immunopathology is warranted.

REFERENCES

1. Dash D, Choudhary R, Ramanujam B, Vasantha PM, Tripathi M. Paraneoplastic syndrome mimicking progressive supranuclear palsy. *J Clin Neurosci* 2016

Oct;**32**:162–3. doi:10.1016/j.jocn.2016.02.032. Epub 2016 Jun 16. PMID: 27318371.

2. Takkar A, Mehta S, Gupta N, Bansal S, Lal V. Anti-RI antibody associated progressive supranuclear palsy like presentation in a patient with breast carcinoma. *J Neuroimmunol* 2020 Oct 15;**347**:577345. doi:10.1016/j.jneuroim.2020.577345. Epub 2020 Jul 26. PMID: 32763584.
3. Tan JH, Goh BC, Tambyah PA, Wilder-Smith E. Paraneoplastic progressive supranuclear palsy syndrome in a patient with B-cell lymphoma. *Parkinsonism Relat Disord* 2005 May;**11**(3):187–91. doi:10.1016/j.parkreldis.2004.09.003. PMID: 15823484.

117

MULTIPLE SCLEROSIS PRESENTING AS A RAPIDLY PROGRESSIVE DEMENTIA

¹Natasha Gerbis, ^{2,3}John DE Parratt. ¹Northern Beaches Hospital, Frenchs Forest, NSW, Australia; ²Royal North Shore Hospital, St Leonards, NSW, Australia; ³University of Sydney, Sydney, NSW, Australia

10.1136/bmjno-2021-ANZAN.117

Objectives Rapidly progressive dementias manifest with cognitive decline that progresses over weeks to months. It is rare for dementia to present early in the course of multiple sclerosis (MS). However, several case series on rapidly progressive dementia include a small number of patients with MS, and one small case series specifically examined dementia presenting within five years of MS diagnosis.

Methods Case study.

Results A 66 year old woman presented to hospital with progressive left upper limb weakness and subacute cognitive decline over six to nine months. MRI brain revealed a right frontoparietal tumefactive lesion. Oligoclonal bands were detected in the CSF and a brain biopsy confirmed demyelination. The patient's serum was tested in our research lab and revealed a novel antibody.

The patient experienced a fluctuating clinical course but responded well to treatment with intravenous (IV) methylprednisolone, IV immunoglobulin (IVIG) and Cyclophosphamide. Unfortunately, further deterioration occurred five months after treatment with Cyclophosphamide and Rituximab was initiated. Clinical improvement in cognition was again observed, albeit briefly.

Six months later, the patient died due to bronchopneumonia. The period from initial presentation to death spanned 30 months. A non-coronial autopsy was performed and revealed widespread incomplete cortical myelin loss and atrophy.

Conclusions Although a few cases have previously been reported in the published medical literature, dementia in the early stages of MS is extremely rare and may in fact be due to a distinct immunopathologic process.

REFERENCE

1. Zhang W, et al. Analysis of clinical features for 8 patients with autoimmune dementia. *Zhonghua Yi Xue Za Zhi*. 2014 Feb 11;**94**(5):359–63.
2. Mendes MF, et al. Early and severe cognitive impairment in multiple sclerosis. *Dement Neuropsychol* 2012 Jan-Mar;**6**(1):48–52.